Consensus or Controversy? Documenting and Discussing Investigators’ Approaches to the Management of Myelofibrosis

Accreditation types: 1.25 ABIM MOC, CME

Expires: August 2027

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Claire Harrison

Faculty

Claire Harrison

Professor

Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Professor of Myeloproliferative Neoplasms

Raajit K Rampal

Faculty

Raajit K Rampal

MD, PhD

Memorial Sloan Kettering Cancer Center, New York, New York

Associate Member, Director, MPN and Rare Hematologic Malignancies Program, Director, Center for Hematologic Malignancies

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of myelofibrosis.

LEARNING OBJECTIVES

  • Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with myelofibrosis (MF) regarding their long-term prognosis.
  • Analyze how age, performance status and other biological and disease-related factors affect the selection and sequencing of therapy for patients with primary and secondary MF.
  • Appraise available research findings informing the safety and efficacy of approved JAK inhibitors for patients with MF.
  • Evaluate published research findings with JAK inhibitors for patients with MF and anemia to optimize decision-making for this population.
  • Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia.
  • Understand the biological rationale for the inhibition of exportin 1 (XPO1) for patients with MF, and reflect on available and emerging research findings with XPO1 inhibitors in combination with JAK inhibitors as front-line treatment.
  • Recall available research findings with combination regimens incorporating JAK inhibitors and other novel investigational agents, and consider the role of these emerging approaches in treatment.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better, and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Harrison — Advisory Committees: Alethiomics, AOP Health, Calytrix Bio, Galecto Inc, GSK, Incyte Corporation, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, Menarini Group, Novartis, Stemline Therapeutics Inc, Takeda Pharmaceutical Company Limited; Consulting Agreements: Alethiomics, AOP Health, Calytrix Bio, Galecto Inc, GSK, Incyte Corporation, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, Menarini Group, MSD, Novartis, Stemline Therapeutics Inc, Takeda Pharmaceutical Company Limited; Contracted Research: GSK, Novartis; Data and Safety Monitoring Boards/Committees: Deciphera Pharmaceuticals Inc, Silence Therapeutics, Takeda Pharmaceutical Company Limited; Speakers Bureaus: GSK, Menarini Group, MSD, Novartis, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: Owner private LLP, trustee MPN Voice and Blood Cancer UK. Dr Rampal — Consulting Agreements: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Galecto Inc, GSK, Incyte Corporation, Jazz Pharmaceuticals Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Opna Bio, PharmaEssentia, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Zentalis Pharmaceuticals; Contracted Research: BioMed Valley Discoveries, Incyte Corporation, MorphoSys, Ryvu Therapeutics, Stemline Therapeutics Inc, Zentalis Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Merck.

CONTRIBUTING CLINICAL INVESTIGATORS
Prithviraj Bose, MD — Advisory Committees: Blueprint Medicines, Deciphera Pharmaceuticals Inc, Geron Corporation, GSK, Karyopharm Therapeutics, Novartis, PharmaEssentia, RayThera, Sumitomo Pharma America, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Bristol Myers Squibb, Cogent Biosciences, Damora Therapeutics, Disc Medicine, Incyte Corporation, Ionis Pharmaceuticals Inc, Merck, V6, Vyne Therapeutics Inc; Contracted Research: Ajax Therapeutics, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, Disc Medicine, Geron Corporation, GSK, Incyte Corporation, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, Merck, Morphosys, Novartis, Sumitomo Pharma America, Telios Pharma Inc. Andrew T Kuykendall, MD — Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Incyte Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Karyopharm Therapeutics, MorphoSys; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, Janssen Biotech Inc, MorphoSys, Protagonist Therapeutics; Data and Safety Monitoring Boards/Committees: Geron Corporation. John Mascarenhas, MD — Advisory Committees: Cogent Biosciences, Galecto Inc; Consulting Agreements: Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, GSK, Incyte Corporation, Italfarmaco SpA, Karyopharm Therapeutics, Merck, Novartis, Opna Bio, Pfizer Inc, PharmaEssentia, Sobi, Sumitomo Pharma America, Takeda Pharmaceuticals USA Inc; Contracted Research: Ajax Therapeutics, Bristol Myers Squibb, Disc Medicine, Dompé, Geron Corporation, Incyte Corporation, Italfarmaco SpA, Kartos Therapeutics, Karyopharm Therapeutics, Novartis, PharmaEssentia, Sobi; Data and Safety Monitoring Boards/Committees: Kartos Therapeutics; Stock Options — Private Companies: Cogent Biosciences. Abdulraheem Yacoub, MD — Consulting Agreements: Blueprint Medicines, GSK, Incyte Corporation, Karyopharm Therapeutics, Novartis, PharmaEssentia, Protagonist Therapeutics, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Contracted Research: CTI BioPharma, a Sobi Company, Stemline Therapeutics Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from GSK and Karyopharm Therapeutics.

Release date: August 2026
Expiration date: August 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Prof Harrison

Mascarenhas J et al. Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial. ASCO 2026;Abstract LBA6500.

Mascarenhas J et al. Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY phase 3 study design. Future Oncol 2025;21(7):807-13. Abstract

Mascarenhas JO et al. Results from the randomized, multicenter, global phase 3 BOREAS study: Navtemadlin versus best available therapy in JAK inhibitor relapsed/refractory myelofibrosis. ASH 2024;Abstract 1000.

Mascarenhas J et al. Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis. J Clin Oncol 2021;39(26):2881-92. Abstract

Rampal R et al. Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK inhibitor–naive myelofibrosis: 96-week results from the phase III MANIFEST-2 study. ASH 2025;Abstract 910.

Rampal RK et al. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: A randomized phase 3 trial. Nat Med 2025;31(5):1531-8. Abstract

Verstovsek S et al. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies. Cancer 2023;129(11):1681-90. Abstract

Verstovsek S et al. Does early intervention in myelofibrosis impact outcomes? A pooled analysis of the COMFORT I and II studies. ASH 2021;Abstract 1505.

Dr Rampal

Gerds AT et al. Determining the recommended dose of pacritinib: Results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv 2020;4(22):5825-35. Abstract

Gerds AT et al. Duration of response to luspatercept in patients (pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF) — Updated data from the phase 2 ACE-536-MF-001 study. ASH 2020;Abstract 47.

Maffioli M et al. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv 2022;6(6):1855-64. Abstract

Mesa RA et al. MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. ASCO 2022;Abstract 7002.

Oh ST et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. ASH 2022;Abstract 1518.

Oh ST et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv 2020;4(18):4282-91. Abstract

Vachhani P et al. Platelet response in pacritinib-treated patients with cytopenic myelofibrosis: A retrospective analysis of PERSIST-2 and PAC203 studies. ASH 2023;Abstract 4554.

Verstovsek S et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 2023;401(10373):269-80. Abstract

Verstovsek S et al. Robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor naïve and previously JAK inhibitor treated intermediate/high risk myelofibrosis patients. ASH 2020;Abstract 51.

A Case-Based Exploration of Current and Future Directions in Myelofibrosis — Where We Are, Where We’re Going

A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting

Program Schedule — Central Time
Friday, December 11, 2026
2:45 PM – 3:15 PM — Registration and Light Snack
3:15 PM – 5:15 PM — Educational Meeting

Location
Sheraton New Orleans Hotel
500 Canal Street
New Orleans, Louisiana
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

No registration fee is charged for this event. Preregistration is required for in-person attendance in New Orleans as seating is limited.

Faculty

Lucia Masarova

MD

The University of Texas MD Anderson Cancer Center, Houston, Texas

Assistant Professor in the Department of Leukemia

Ruben A Mesa

Faculty

Ruben A Mesa

MD

Advocate Health, Winston-Salem, North Carolina

Senior Vice President, President of Advocate Health Cancer National Service Line

Atrium Health Levine Cancer, Winston-Salem, North Carolina

President

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

Executive Director

Wake Forest University School of Medicine, Winston-Salem, North Carolina

Vice Dean for Cancer Programs, The Charles L Spurr MD Professor of Medicine

Faculty

Francesco Passamonti

MD

University of Milan, Milan, Italy

Professor of Hematology, Department of Oncology and Hemato-Oncology

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

Director, Hematology

Raajit K Rampal

Faculty

Raajit K Rampal

MD, PhD

Memorial Sloan Kettering Cancer Center, New York, New York

Associate Member, Director, MPN and Rare Hematologic Malignancies Program, Director, Center for Hematologic Malignancies

Andrew T Kuykendall

Moderator

Andrew T Kuykendall

MD

Moffitt Cancer Center, Tampa, Florida

Associate Member, Department of Malignant Hematology

University of South Florida, Tampa, Florida

Associate Professor, Department of Oncologic Sciences

This activity is supported by educational grants from Bristol Myers Squibb, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, and Novartis.

Join us on Friday, December 11th from 3:15 PM to 5:15 PM central time (4:15 PM to 6:15 PM eastern time).

MODULE 1: Current Clinical Decision-Making for Patients with Myelofibrosis (MF) in the Absence of Severe Cytopenias

MODULE 2: Managing MF in Patients with Anemia

MODULE 3: Managing MF in Patients with Thrombocytopenia

MODULE 4: Novel Approaches for MF Potentially Nearing the Clinic

MODULE 5: Other Promising Novel Agents Under Investigation in MF

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of myelofibrosis (MF).

Learning Objectives
At the conclusion of this activity, participants should be able to

  • Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with MF regarding their long-term prognosis.
  • Analyze how age, performance status and other biological and disease-related factors affect the decision to initiate therapy and the subsequent selection of treatment for patients with primary and secondary MF.
  • Appraise available research informing the safety and efficacy of approved JAK inhibitors for patients with MF, including those with anemia, thrombocytopenia or compromised renal function, and personalize treatment recommendations based on this information.
  • Evaluate published research findings with JAK inhibitors for MF and anemia to optimize decision-making for this patient population.
  • Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia.
  • Understand the biological rationale for the inhibition of exportin 1 (XPO1) in patients with MF, and reflect on available and emerging research findings with XPO1 inhibitors in combination with JAK inhibition as front-line treatment.
  • Recall available research findings with combination regimens incorporating JAK inhibitors and other novel investigational agents, and consider the potential role of these emerging approaches.
  • Recognize the spectrum, frequency and severity of side effects associated with JAK inhibitors and other therapies for MF, and implement a plan of care to recognize, prevent and manage toxicities.
  • Assess the mechanism of action, available research findings, and ongoing investigation of other novel agents in MF, and consider the potential clinical application of these approaches.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
Dr Mesa — Consulting Agreements: Bristol Myers Squibb, Genentech, a member of the Roche Group, Geron Corporation, GSK, Incyte Corporation, Lilly, PharmaEssentia, Sobi, Takeda Pharmaceuticals USA Inc, Telios Pharma Inc; Contracted Research: Incyte Corporation, PharmaEssentia; Data and Safety Monitoring Boards/Committees: Geron Corporation, Kartos Therapeutics, Telios Pharma Inc. Dr Passamonti — Advisory Committees: AbbVie Inc, Bristol Myers Squibb, GSK, Kartos Therapeutics, Karyopharm Therapeutics, Menarini Group, Novartis, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Pharma, Takeda Pharmaceutical Company Limited; Data and Safety Monitoring Boards/Committees: Menarini Group (myeloma study); Speakers Bureaus: AOP Orphan Pharmaceuticals GmbH, Bristol Myers Squibb, GSK, Incyte Corporation, Menarini Group, Novartis, Stemline Therapeutics Inc. Dr Rampal — Consulting Agreements: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Galecto Inc, GSK, Incyte Corporation, Jazz Pharmaceuticals Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Opna Bio, PharmaEssentia, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Zentalis Pharmaceuticals; Contracted Research: BioMed Valley Discoveries, Incyte Corporation, MorphoSys, Ryvu Therapeutics, Stemline Therapeutics Inc, Zentalis Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Merck. Additional faculty to be confirmed.

MODERATOR
To be announced.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, and Novartis.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

Register for webcast

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Consensus or Controversy? Documenting and Discussing Investigators’ Approaches to the Management of Myelofibrosis

A CME/MOC-Accredited Virtual Event Held Adjunct with the 2026 ASCO® Annual Meeting

Tuesday, June 2, 2026
5:00 PM – 6:00 PM ET (4:00 PM – 5:00 PM CT)
Live CME/MOC-accredited webinar

Faculty

Claire Harrison

Faculty

Claire Harrison

Professor

Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Professor of Myeloproliferative Neoplasms

Raajit K Rampal

Faculty

Raajit K Rampal

MD, PhD

Memorial Sloan Kettering Cancer Center, New York, New York

Associate Member, Director, MPN and Rare Hematologic Malignancies Program, Director, Center for Hematologic Malignancies

Neil Love

Moderator

Neil Love

MD

Research To Practice

Miami, Florida

This activity is supported by educational grants from GSK and Karyopharm Therapeutics.

Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Topics to Be Discussed 

  • Biology of Myelofibrosis (MF); Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias 
  • Managing MF for Patients with Anemia and Thrombocytopenia

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals involved in the treatment of myelofibrosis.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with myelofibrosis (MF) regarding their long-term prognosis.  
  • Analyze how age, performance status and other biological and disease-related factors affect the selection and sequencing of therapy for patients with primary and secondary MF. 
  • Appraise available research findings informing the safety and efficacy of approved JAK inhibitors for patients with MF. 
  • Evaluate published research findings with JAK inhibitors for patients with MF and anemia to optimize decision-making for this population. 
  • Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia. 
  • Understand the biological rationale for the inhibition of exportin 1 (XPO1) for patients with MF, and reflect on available and emerging research findings with XPO1 inhibitors in combination with JAK inhibitors as front-line treatment. 
  • Recall available research findings with combination regimens incorporating JAK inhibitors and other novel investigational agents, and consider the role of these emerging approaches in treatment.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Harrison — Advisory Committees: Alethiomics, AOP Health, Calytrix Bio, Galecto Inc, GSK, Incyte Corporation, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, Menarini Group, Novartis, Stemline Therapeutics Inc, Takeda Pharmaceutical Company Limited; Consulting Agreements: Alethiomics, AOP Health, Calytrix Bio, Galecto Inc, GSK, Incyte Corporation, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, Menarini Group, MSD, Novartis, Stemline Therapeutics Inc, Takeda Pharmaceutical Company Limited; Contracted Research: GSK, Novartis; Data and Safety Monitoring Boards/Committees: Deciphera Pharmaceuticals Inc, Silence Therapeutics, Takeda Pharmaceutical Company Limited; Speakers Bureaus: GSK, Menarini Group, MSD, Novartis, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: Owner private LLP, trustee MPN Voice and Blood Cancer UK. Dr Rampal — Consulting Agreements: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Galecto Inc, GSK, Incyte Corporation, Jazz Pharmaceuticals Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Opna Bio, PharmaEssentia, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Zentalis Pharmaceuticals; Contracted Research: BioMed Valley Discoveries, Incyte Corporation, MorphoSys, Ryvu Therapeutics, Stemline Therapeutics Inc, Zentalis Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Merck.

CONTRIBUTING CLINICAL INVESTIGATORS
Prithviraj Bose, MD — Advisory Committees: Blueprint Medicines, Geron Corporation, GSK, Karyopharm Therapeutics, Keros Therapeutics, PharmaEssentia, Sumitomo Dainippon Pharma Oncology Inc; Consulting Agreements: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Geron Corporation, GSK, Incyte Corporation, Ionis Pharmaceuticals Inc, Jubilant Pharma Limited, Karyopharm Therapeutics, Keros Therapeutics, Morphic Therapeutic, a wholly owned subsidiary of Lilly, MorphoSys, Novartis, Ono Pharmaceutical Co Ltd, PharmaEssentia, RayThera, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: Ajax Therapeutics, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, GSK, Incyte Corporation, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Sumitomo Dainippon Pharma Oncology Inc, Telios Pharma Inc. Andrew T Kuykendall, MD — Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Incyte Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Karyopharm Therapeutics, MorphoSys; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, Janssen Biotech Inc, MorphoSys, Protagonist Therapeutics; Data and Safety Monitoring Boards/Committees: Geron Corporation. John Mascarenhas, MD — Consulting Agreements: Bristol Myers Squibb, Disc Medicine, Geron Corporation, GSK, Incyte Corporation, Italfarmaco SpA, Kartos Therapeutics, Karyopharm Therapeutics, Keros Therapeutics, Merck, MorphoSys, Novartis, PharmaEssentia, Roche Laboratories Inc, Sobi, Sumitomo Pharma America; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Disc Medicine, Incyte Corporation, Italfarmaco SpA, Kartos Therapeutics, Karyopharm Therapeutics, Novartis, PharmaEssentia, Sobi; Data and Safety Monitoring Boards/Committees: Incyte Corporation. Abdulraheem Yacoub, MD — Consulting Agreements: Blueprint Medicines, GSK, Incyte Corporation, Karyopharm Therapeutics, Novartis, PharmaEssentia, Protagonist Therapeutics, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Contracted Research: CTI BioPharma, a Sobi Company, Stemline Therapeutics Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from GSK and Karyopharm Therapeutics.

You have successfully registered

See you Tuesday, June 2nd.

Format:

Online
Date & Time:

Tuesday, June 2nd from 5:00 PM – 6:00 PM ET

Expert Second Opinion: Investigators Discuss the Optimal Management of Myelofibrosis and Systemic Mastocytosis

Accreditation types: 2.25 ABIM MOC, CME

Expires: January 2027

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Claire Harrison

Faculty

Claire Harrison

Professor

Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Professor of Myeloproliferative Neoplasms

Andrew T Kuykendall

Faculty

Andrew T Kuykendall

MD

Moffitt Cancer Center, Tampa, Florida

Associate Member, Department of Malignant Hematology

University of South Florida, Tampa, Florida

Associate Professor, Department of Oncologic Sciences

Stephen T Oh

Faculty

Stephen T Oh

MD, PhD

Washington University School of Medicine, St Louis, Missouri

Associate Professor of Medicine, Co-Chief, Division of Hematology

Jeanne Palmer

Faculty

Jeanne Palmer

MD

Mayo Clinic in Arizona, Phoenix, Arizona

Associate Professor of Medicine

Raajit K Rampal

Faculty

Raajit K Rampal

MD, PhD

Memorial Sloan Kettering Cancer Center, New York, New York

Associate Member, Director, MPN and Rare Hematologic Malignancies Program, Director, Center for Hematologic Malignancies

TARGET AUDIENCE
This program is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of myelofibrosis (MF) and systemic mastocytosis (SM).

LEARNING OBJECTIVES

  • Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with MF regarding their long-term prognosis.
  • Analyze how patient age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for primary and secondary MF.
  • Appraise available research findings informing the safety and efficacy of approved JAK inhibitors for patients with MF, including those with thrombocytopenia, anemia or compromised renal function.
  • Evaluate published research findings with JAK inhibitors for patients with MF and anemia to optimize therapeutic decision-making.
  • Assess available research findings with novel investigational strategies, and consider the future clinical application of these approaches for patients with MF.
  • Use an understanding of disease biology to appropriately classify SM, and effectively counsel patients diagnosed with this disease regarding their long-term prognosis.
  • Recall the rationale for targeting the KIT D816V mutation in SM, and appreciate the current role of selective kinase inhibitors of D816V-mutated KIT for patients with indolent and advanced disease.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CE ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHMF25/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Professor Claire Harrison
Professor of Myeloproliferative Neoplasms
Guy’s and St Thomas’ NHS Foundation Trust
London, United Kingdom

Advisory Committees: Galecto Inc, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Keros Therapeutics, Novartis, Silence Therapeutics, Sobi; Consulting Agreements: Galecto Inc, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Keros Therapeutics, Novartis, Silence Therapeutics, Sobi, Takeda Pharmaceutical Company Limited; Contracted Research: Galecto Inc, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Novartis, Silence Therapeutics, Sobi; Data and Safety Monitoring Boards/Committees: Galecto Inc, Incyte Corporation, Novartis, Silence Therapeutics; Speakers Bureaus: AOP Health, GSK, Incyte Corporation, Novartis.

Andrew T Kuykendall, MD
Associate Member, Department of Malignant Hematology
Moffitt Cancer Center
Associate Professor, Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Incyte Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Karyopharm Therapeutics, MorphoSys; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, Janssen Biotech Inc, MorphoSys, Protagonist Therapeutics; Data and Safety Monitoring Boards/Committees: Geron Corporation.

Stephen T Oh, MD, PhD
Professor of Medicine
Co-Chief, Division of Hematology
Washington University School of Medicine
St Louis, Missouri

Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation, Morphic Therapeutic, a wholly owned subsidiary of Lilly, MorphoSys, Protagonist Therapeutics; Stock Options — Private Companies: Harmonic Discovery, Phoenix Molecular Designs.

Jeanne Palmer, MD
Associate Professor of Medicine
Mayo Clinic in Arizona
Phoenix, Arizona

Presentation (Money to Institution — Not Speakers Bureau): CTI BioPharma, a Sobi Company.

Raajit K Rampal, MD, PhD
Associate Member, Director
MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Galecto Inc, GSK, Incyte Corporation, Jazz Pharmaceuticals Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Opna Bio, PharmaEssentia, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Zentalis Pharmaceuticals; Contracted Research: BioMed Valley Discoveries, Incyte Corporation, MorphoSys, Ryvu Therapeutics, Stemline Therapeutics Inc, Zentalis Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Merck.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Blueprint Medicines, Bristol Myers Squibb, GSK, and Incyte Corporation.

Release date: January 2026
Expiration date: January 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Palmer

Al-Ali HK et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol 2020;189(5):888-903. Abstract

Al-Ali HK et al. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. Leuk Lymphoma 2016;57(10):2464-7. Abstract

Cervantes F et al. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: The REALISE phase 2 study. Leukemia 2021;35(12):3455-65. Abstract

Gerds A et al. Ruxolitinib rechallenge can improve constitutional symptoms and splenomegaly in patients with myelofibrosis: A case series. Clin Lymphoma Myeloma Leuk 2018;18(11):e463-8. Abstract

Gupta V et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica 2016;101(12):e482-4. Abstract

Harrison CN et al. Overall and progression-free survival in patients treated with fedratinib as first-line myelofibrosis (MF) therapy and after prior ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 trials. EHA 2021;Abstract S203.

Harrison CN et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol 2020;95(6):594-603. Abstract

Harrison CN et al. Case series of potential Wernicke’s encephalopathy in patients treated with fedratinib. ASH 2017;Abstract 4197.

Harrison CN et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 2017;4(7):e317-24. Abstract

Harrison CN et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016;30(8):1701-7. Abstract

Harrison CN et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98. Abstract

Kuykendall AT et al. Between a rux and a hard place: Evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol;97(3):435-41. Abstract

Maffioli M et al. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv 2022;6(6):1855-64. Abstract

Newberry KJ et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 2017;130(9):1125-1131. Abstract

Palandri F et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer 2020;126(6):1243-52. Abstract

Pardanani A et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol 2015;1(5):643-51. Abstract

Scott BL et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 2017;35(11):1154-61. Abstract

Verstovsek S et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls. Blood 2012;120(6):1202-9. Abstract

Verstovsek S et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807. Abstract

Zhang Q et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: A putative mechanism for the onset of Wernicke’s encephalopathy. Drug Metab Dispos 2014;42(10):1656-62. Abstract

Dr Oh

Gerds AT et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): An updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol 2023;10(9):e735-46. Abstract

Gupta V et al. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. Leuk Lymphoma 2024;65(7):965-77. Abstract

Naymagon L, Mascarenhas L. Myelofibrosis-related anemia: Current and emerging therapeutic strategies. Hemasphere 2017;1(1). Abstract

Nicolosi M et al. Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: Analysis based on 1109 consecutive patients. Leukemia 2018;32(5):1254-8. Abstract

Oh ST et al. Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis. EJHaem 2024;5(1):105-16. Abstract

Oh ST et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 2023;7(19):5835-42. Abstract

Oh ST et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv 2020;4(18):4282-91. Abstract

Tefferi A et al. One thousand patients with primary myelofibrosis: The Mayo Clinic experience. Mayo Clin Proc 2012;87(1):25-33. Abstract

Verstovsek S et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 2023;401(10373):269-80. Abstract

Verstovsek S et al. MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol 2021;17(12):1449-58. Abstract

Verstovsek S et al. Robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor naïve and previously JAK inhibitor treated intermediate/high risk myelofibrosis patients. ASH 2020;Abstract 54.

Dr Rampal

Ajufo H et al. Pacritinib response is associated with overall survival in myelofibrosis: PERSIST-2 landmark analysis of survival. Eur J Haematol 2025;114(2):238-47. Abstract

Alhuraiji A et al. Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: A single-center experience in 1100 myelofibrosis patients. ASCO 2016;Abstract 7068.

Gerds AT et al. Determining the recommended dose of pacritinib: Results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv 2020;4(22):5825-35. Abstract

Hernandez-Boluda JC et al. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. Br J Haematol 2018;181(3):397-400. Abstract

Marcellino BK et al. The myelodepletive phenotype in myelofibrosis: Clinical relevance and therapeutic implication. Clin Lymphoma Myeloma Leuk 2020;20(7):415-21. Abstract

Masarova L et al. Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported. Leuk Res 2020;91:106338. Abstract

Masarova L et al. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol 2018;100(3):257-63. Abstract

Mascarenhas J et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. JAMA Oncol 2018;4(5):652-9. Abstract

Scotch AH et al. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leuk Res 2017;63:34-40. Abstract

Vachhani P et al. Platelet response in pacritinib-treated patients with cytopenic myelofibrosis: A retrospective analysis of PERSIST-2 and PAC203 studies. ASH 2023;Abstract 4554.

Prof Harrison

Bose P et al. Odyssey: A phase 2 open-label study of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis. ASH 2024;Abstract 3191.2.

Fenaux P et al. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood 2019;133(8):790-4. Abstract

Gerds AT et al. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv 2024;8(17):4511-22. Abstract

Mascarenhas J et al. INCA33989 is a novel, first in class, mutant calreticulin-specific monoclonal antibody that demonstrates safety and efficacy in patients with essential thrombocythemia (ET). EHA 2025;Abstract LBA4002.

Mascarenhas J et al. Results from the randomized, multicenter, global phase 3 BOREAS study: Navtemadlin versus best available therapy in JAK inhibitor relapsed/refractory myelofibrosis. ASH 2024;Abstract 1000.

Mead A et al. Interim analysis of Promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib. ASH 2024;Abstract 3186.

Vachhani P et al. Disease-modifying activity of navtemadlin (NVTM) correlated with survival outcomes in Janus kinase inhibitor (JAKI) relapsed or refractory (R/R) myelofibrosis (MF) patients (PTS). EHA 2023;Abstract S214.

Vannucchi AM et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor-naive patients with myelofibrosis: 72-week follow-up with long-term efficacy outcomes of the phase III MANIFEST-2 study. EHA 2025;Abstract S223.

Dr Kuykendall

Bose P et al. Initial results from Summit: An ongoing, 3-part, multi-center, randomized, double-blind, placebo-controlled phase 2 clinical study of bezuclastinib in adult patients with nonadvanced systemic mastocytosis (NonAdvSM). ASH 2023;Abstract 77.

Castells M et al. Efficacy and safety of avapritinib in indolent systemic mastocytosis (ISM): Results from the double-blind placebo-controlled PIONEER study. AAAAI 2023;Abstract 627.

Chifotides HT, Bose P. SOHO state of the art update and next questions: Current and emerging therapies for systemic mastocytosis. Clin Lymphoma Myeloma Leuk 2025;25(1):1-12. Abstract

DeAngelo DJ et al. An updated analysis on safety and efficacy of avapritinib in patients with advanced systemic mastocytosis from the Explorer clinical study: Long-term efficacy and safety. ASH 2022;Abstract.

Gotlib J et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: Interim analysis of the phase 2 PATHFINDER trial. Nat Med 2021;27(12):2192-9. Abstract

Mesa RA et al. Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM patient survey. Cancer 2022 Oct;128(20):3691-9. Abstract

Mukherjee S et al. Decreased survival among patients with indolent systemic mastocytosis: A population-level retrospective cohort analysis using healthcare claims dataset. ASH 2023;Abstract 75.

Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol 2019;94(3):363-77. Abstract

Radia DH et. al. Avapritinib as first-line therapy in patients with advanced systemic mastocytosis: Efficacy and safety from the PATHFINDER clinical study. ASH 2022;Abstract.

Tashi T et al. Elenestinib, an investigational, next generation KIT D816V inhibitor, reduces mast cell burden, improves symptoms, and has a favorable safety profile in patients with indolent systemic mastocytosis: Analysis of the HARBOR trial. ASH 2023;Abstract 76.

Valent P et al. Harmonization of diagnostic criteria in mastocytosis for use in clinical practice: WHO vs ICC vs AIM/ECNM. J Allergy Clin Immunol Pract 2024;12(12):3250-60.e5. Abstract

  • ASH 2025
  • MF

Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting — Myelofibrosis Edition

Accreditation types: 1 ABIM MOC, CME

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Raajit K Rampal

Raajit K Rampal

MD

Memorial Sloan Kettering Cancer Center, New York, New York

Associate Member, Director – MPN and Rare Hematologic Malignancies Program, Director – Center for Hematologic Malignancies

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of myelofibrosis.

LEARNING OBJECTIVES

  • Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with myelofibrosis (MF) regarding their long-term prognosis.
  • Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with primary and secondary MF.
  • Appraise available research findings informing the safety and efficacy of approved JAK inhibitors for MF, including in patients with thrombocytopenia, anemia or compromised renal function.
  • Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia.
  • Evaluate published research findings with JAK inhibitors for MF in patients with anemia in order to optimize decision-making for this population.
  • Assess available research findings with combination regimens incorporating JAK inhibitors and other novel therapies, and consider the potential clinical application of these approaches.
  • Increase participation in active research protocols by counseling appropriately selected patients regarding the biological rationale for and available efficacy and safety data with novel investigational agents and strategies for MF.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Video Lecture: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1 (video) and 0.75 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:

Video Interview: ResearchToPractice.com/OncologyTodayPostASH25/MF/Video and evaluation ResearchToPractice.com/OncologyTodayPostASH25/MF/Video/CME.

Video Lecture: ResearchToPractice.com/OncologyTodayPostASH25/MF/Presentation and evaluation ResearchToPractice.com/OncologyTodayPostASH25/MF/Presentation/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Raajit K Rampal, MD
Associate Member, Director – MPN and Rare Hematologic Malignancies Program
Director – Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Galecto Inc, GSK, Incyte Corporation, Jazz Pharmaceuticals Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Opna Bio, PharmaEssentia, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Zentalis Pharmaceuticals; Contracted Research: BioMed Valley Discoveries, Incyte Corporation, MorphoSys, Ryvu Therapeutics, Stemline Therapeutics Inc, Zentalis Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Merck.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from Incyte Corporation.

Release date: April 2025
Expiration date: April 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Al-Ali HK et al. Efficacy and safety of fedratinib in patients with myelofibrosis and low baseline platelet counts in the phase 3 randomized FREEDOM2 trial. ASH 2024;Abstract 482.

Duan M et al. The efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated myelofibrosis patients: The interim analysis of a prospective, open-label, multicenter, parallel-cohort, Phase 2 study. ASH 2024;Abstract 1002.

El Chaer F et al. Nuvisertinib (TP-3654), an investigational selective PIM2 kinase inhibitor, showed durable clinical response and sustained hematological improvement in patients with relapsed/refractory myelofibrosis. ASH 2024;Abstract 655.

Gangat N et al. A phase 1b study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia. ASH 2024;Abstract 657.

Harrison C et al. Hematological improvement and other clinical benefits of elritercept as monotherapy and in combination with myelofibrosis from the ongoing phase 2 RESTORE trial. ASH 2024;Abstract 997.

Masarova L et al. A Phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal responses to ruxolitinib. ASH 2024;Abstract 999.

Mascarenhas JO et al. Imetelstat versus best available therapy in patients with immediate-2 or high-risk myelofibrosis relapsed or refractory Janus kinase inhibitor in IMpactMF, a randomized, open-label, Phase 3 trial. ASH 2024;Abstract 1808.1.

Mascarenhas JO et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, Phase 3 study. ASH 2024;Abstract 3178.

Mascarenhas JO et al. Results from the randomized, multicenter, global phase 3 study BOREAS: Navtemadlin versus best available therapy in JAK inhibitor relapsed/refractory myelofibrosis. ASH 2024;Abstract 1000.

Mascarenhas J et al. Trial update from IMproveMF, an ongoing, open-label, dose-escalation and -expansion phase 1/1b trial to evaluate the safety, pharmacokinitics, and clinical activity of the novel combinations of imetelstat with ruxolitinib in patients with intermediate-1, intermediate-2, or high-risk myelofibrosis. ASH 2024;Abstract 998.

Vachhani P et al. Clinical outcomes in patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications. ASH 2024;Abstract 4546.

Vachhani P et al. POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis who have a suboptimal response to ruxolitinib. ASH 2024;Abstract 1808.2.

Watts JM et al. Safety and efficacy of bromodomain and extra-terminal inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis and other advanced myeloid neoplasms: A Phase 1 study. ASH 2024;Abstract 658.

Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting — Myelofibrosis Edition

Accreditation types: 0.75 ABIM MOC, CME

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Raajit K Rampal

Raajit K Rampal

MD

Memorial Sloan Kettering Cancer Center, New York, New York

Associate Member, Director – MPN and Rare Hematologic Malignancies Program, Director – Center for Hematologic Malignancies

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of myelofibrosis.

LEARNING OBJECTIVES

  • Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with myelofibrosis (MF) regarding their long-term prognosis.
  • Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with primary and secondary MF.
  • Appraise available research findings informing the safety and efficacy of approved JAK inhibitors for MF, including in patients with thrombocytopenia, anemia or compromised renal function.
  • Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia.
  • Evaluate published research findings with JAK inhibitors for MF in patients with anemia in order to optimize decision-making for this population.
  • Assess available research findings with combination regimens incorporating JAK inhibitors and other novel therapies, and consider the potential clinical application of these approaches.
  • Increase participation in active research protocols by counseling appropriately selected patients regarding the biological rationale for and available efficacy and safety data with novel investigational agents and strategies for MF.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Video Lecture: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1 (video) and 0.75 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:

Video Interview: ResearchToPractice.com/OncologyTodayPostASH25/MF/Video and evaluation ResearchToPractice.com/OncologyTodayPostASH25/MF/Video/CME.

Video Lecture: ResearchToPractice.com/OncologyTodayPostASH25/MF/Presentation and evaluation ResearchToPractice.com/OncologyTodayPostASH25/MF/Presentation/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Raajit K Rampal, MD
Associate Member, Director – MPN and Rare Hematologic Malignancies Program
Director – Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Galecto Inc, GSK, Incyte Corporation, Jazz Pharmaceuticals Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Opna Bio, PharmaEssentia, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Zentalis Pharmaceuticals; Contracted Research: BioMed Valley Discoveries, Incyte Corporation, MorphoSys, Ryvu Therapeutics, Stemline Therapeutics Inc, Zentalis Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Merck.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from Incyte Corporation.

Release date: April 2025
Expiration date: April 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Al-Ali HK et al. Efficacy and safety of fedratinib in patients with myelofibrosis and low baseline platelet counts in the phase 3 randomized FREEDOM2 trial. ASH 2024;Abstract 482.

Duan M et al. The efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated myelofibrosis patients: The interim analysis of a prospective, open-label, multicenter, parallel-cohort, Phase 2 study. ASH 2024;Abstract 1002.

El Chaer F et al. Nuvisertinib (TP-3654), an investigational selective PIM2 kinase inhibitor, showed durable clinical response and sustained hematological improvement in patients with relapsed/refractory myelofibrosis. ASH 2024;Abstract 655.

Gangat N et al. A phase 1b study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia. ASH 2024;Abstract 657.

Harrison C et al. Hematological improvement and other clinical benefits of elritercept as monotherapy and in combination with myelofibrosis from the ongoing phase 2 RESTORE trial. ASH 2024;Abstract 997.

Masarova L et al. A Phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal responses to ruxolitinib. ASH 2024;Abstract 999.

Mascarenhas JO et al. Imetelstat versus best available therapy in patients with immediate-2 or high-risk myelofibrosis relapsed or refractory Janus kinase inhibitor in IMpactMF, a randomized, open-label, Phase 3 trial. ASH 2024;Abstract 1808.1.

Mascarenhas JO et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, Phase 3 study. ASH 2024;Abstract 3178.

Mascarenhas JO et al. Results from the randomized, multicenter, global phase 3 study BOREAS: Navtemadlin versus best available therapy in JAK inhibitor relapsed/refractory myelofibrosis. ASH 2024;Abstract 1000.

Mascarenhas J et al. Trial update from IMproveMF, an ongoing, open-label, dose-escalation and -expansion phase 1/1b trial to evaluate the safety, pharmacokinitics, and clinical activity of the novel combinations of imetelstat with ruxolitinib in patients with intermediate-1, intermediate-2, or high-risk myelofibrosis. ASH 2024;Abstract 998.

Vachhani P et al. Clinical outcomes in patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications. ASH 2024;Abstract 4546.

Vachhani P et al. POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis who have a suboptimal response to ruxolitinib. ASH 2024;Abstract 1808.2.

Watts JM et al. Safety and efficacy of bromodomain and extra-terminal inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis and other advanced myeloid neoplasms: A Phase 1 study. ASH 2024;Abstract 658.